<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475969</url>
  </required_header>
  <id_info>
    <org_study_id>6089</org_study_id>
    <secondary_id>F1J-MC-HMDT</secondary_id>
    <nct_id>NCT00475969</nct_id>
  </id_info>
  <brief_title>Duloxetine vs Placebo in the Treatment of General Anxiety</brief_title>
  <official_title>Duloxetine Hydrochloride Once Daily Compared With Placebo in the Treatment of Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of
      generalized anxiety disorder (GAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      duloxetine 60 to 120 mg once daily (QD) and placebo 11 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAMA) total score (Hamilton 1959)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS) Global Functional Impairment score (Sheehan 1983)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression Scale (HADS; Zigmond and Snaith 1983)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions of Improvement scale (CGI-Improvement; Guy 1976)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impressions of Improvement scale (PGI-Improvement; Guy 1976)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Questionnaire-Somatic Subscale (SQ-SS)</measure>
  </secondary_outcome>
  <enrollment>327</enrollment>
  <condition>Anxiety</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients at least 18 years of age presenting with generalized
             anxiety disorder (GAD) based on the disease diagnostic criteria The patient must
             suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise
             specified (NOS). Symptoms of GAD should not be situational in nature.

          -  Females of childbearing potential (not surgically sterilized and between menarche and
             1 year postmenopause) who are not breastfeeding; test negative for pregnancy at the
             time of enrollment based on a urine pregnancy test; and agree to use a reliable method
             of birth control during the study and for 1 week following the last dose of study
             drug.

          -  Must have a Clinical Global Impressions of Severity (CGI-Severity) score of greater
             than or equal to 4 at Visit 1 and Visit 2.

          -  At Visit 1, patient must have a Covi Anxiety Scale (CAS) score of greater than or
             equal to 9, no item in the Raskin Depression Scale (RDS) may be greater than 3, and
             the CAS must be greater than the RDS.

          -  Must have a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of
             greater than or equal to 10 at Visit 1.

        Exclusion Criteria:

          -  Any current and primary DSM-IV Axis I diagnosis other than GAD.

               -  Patients diagnosed with or who have a history of major depressive disorder (MDD)
                  within the past 6 months or

               -  Patients diagnosed with or who have a history of Panic Disorder, Post-Traumatic
                  Stress Disorder (PTSD), or an eating disorder within the past year or

               -  Patients who have been diagnosed with Obsessive Compulsive Disorder (OCD),
                  Bipolar Affective Disorder, psychosis, factitious disorder, or somatoform
                  disorders during their lifetime.

          -  The presence of an Axis II disorder or history of antisocial behavior, which, in the
             judgment of the investigator, would interfere with compliance with the study protocol.

          -  Benzodiazepine use 14 days prior to Visit 2.

          -  Patients judged clinically to be at serious suicidal risk, or patients who, in the
             opinion of the investigator, are poor medical or psychiatric risks for study
             completion.

          -  Have received treatment within the last 30 days with a drug (not including study drug)
             that has not received regulatory approval for any indication at the time of study
             entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>May 17, 2007</last_update_submitted>
  <last_update_submitted_qc>May 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

